Company profile

PFE stock data



7 Nov 19
7 Dec 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 12.68B 13.26B 13.12B 13.98B
Net income 7.68B 5.05B 3.88B -393M
Diluted EPS 1.36 0.89 0.68 -0.05
Net profit margin 60.57% 38.04% 29.61% -2.81%
Operating income* 11.13B 4.52B 4.68B -588M
Net change in cash 1B -153M 798M -2.42B
Cash on hand 2.79B 1.78B 1.94B 1.14B
Cost of revenue 2.6B 2.58B 2.43B 3.08B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 53.65B 52.55B 52.82B
Net income 11.15B 21.31B 7.22B 6.96B
Diluted EPS 1.87 3.52 1.17 1.11
Net profit margin 20.79% 40.55% 13.66%
Operating income* 13.17B 13.53B 9.51B 10.14B
Net change in cash -203M -1.25B -1.05B 298M
Cash on hand 1.14B 1.34B 2.6B 3.64B
Cost of revenue 11.25B 11.23B 12.32B 9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

Content analysis ?
8th grade Avg
New words: abandoned, abrocitinib, adjudicated, adjudication, akcea, amlodipine, antisense, attachment, BEACON, bidder, binimetinib, Braftovi, broad, cap, CDI, Chapel, checkpoint, CHMP, clearance, College, confidential, conveyed, copay, copy, creativity, Creek, database, demerger, derecognized, encorafenib, Fabre, FCPA, Glenmark, globulin, heart, Hill, hip, HIPAA, immunosuppression, incidence, infection, Inquiry, introduction, JV, Kit, knee, Likewise, LLP, locked, lymphoproliferative, Mektovi, metabolic, Missouri, NaN, Neulasta, nonsteroidal, OA, Octagam, Panzyga, pegfilgrastim, percent, pharmacovigilance, Pierre, polyneuropathy, PRAC, principle, procedure, qualification, Relpax, Rodino, Russian, Sanford, SC, slightly, superseded, tied, tumor, unamortized, uncertainty, unvested, urgency, Utah, VBP, viii
Removed: annually, Aseptic, avoid, back, biomedical, charitable, convert, deletion, economy, eleven, exon, expedite, extreme, functional, gBRCAm, greatest, Kingdom, men, Modular, pace, Processing, prospective, scaling, social, solvency, substitution, suspected, Venezuelan